Xerion Pharmaceuticals AG is a transatlantic biopharmaceutical company with its headquarters in Munich, Germany and its subsidiary Xerion Pharmaceuticals Inc. based in Cambridge, MA.
Xerion was founded in August 1998 to address the emerging market in functional proteomics and target validation. Since then, Xerion has evolved from a pure technology provider to a company which generates highly qualified drug targets and fully human antibody candidates.
Today, Xerion is well positioned to become a highly integrated biopharmaceutical company.
This transition was enabled by the development of Xstream®. Xstream® is a highly integrated approach that by starting with diseased cells identifies druggable targets and therapeutic antibody leads. Xerion has shown to efficiently manage the Xstream® process resulting in first therapeutic leads within one year while alternative methods take far longer. This unprecedented approach yields disease-relevant drug targets and corresponding therapeutic antibody candidates for drug development.
Xerion sets a high value on quality management system and has been awarded the ISO 9001: 2000 quality management certificate.